Depression Screening Market Research Report Information By Disease Type (Major Depressive Disorder, Anxiety Distress, Bipolar Disorder, Psychotic Disorders, and Others), By Diagnosis (Psychological Tests, Blood Tests, Pharmacogenomics Testing, and Others), By End-User (Hospitals & Clinics, Home-based, Research Institute, and Academic Institutes), And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032.

Global Depression Screening Market Overview

Depression Screening Market Size was valued at USD 0.67 Billion in 2022. The Depression Screening market industry is projected to grow from USD 0.71 Billion in 2023 to USD 1.12 Billion by 2032, exhibiting a compound annual growth rate (CAGR) of 5.89% during the forecast period (2023 - 2032). Increasing knowledge of mental illnesses and changing the healthcare industry are the key market drivers enhancing market growth.

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

The main purpose of depression screening, commonly called the depression test, is to determine whether the patient is clinically depressed. Depression is a common sickness, but it differs from ordinary melancholy in that it also impacts a person's thought process and behavior. Because medical appointments for depression therapies might take a long time, people must get psychotherapy for depression on time. If conflicting demands continue to impede depression treatment, steps must be done to ensure that patients with chronic physical conditions receive excellent psychological care in primary healthcare. One of the key elements driving the increase and need for depression screening is the rising prevalence of mental diseases worldwide.

The expanding number of patients suffering from psychological diseases and related disorders and the simple accessibility of cutting-edge diagnostic and therapeutic techniques are also fostering the expansion of the global market. Due to the reduced number of prescriptions written for treating anxiety disorders and depression, the market has grown more slowly than expected. Antidepressants are not in great demand because of the general apathy among people toward awareness of the management and treatment of mental health conditions. However, market participants are actively releasing innovative medications to increase market potential. On the other hand, the difficulty of carrying the burden of an increasing number of psychological diseases and the demand for efficient care of disorders related to anxiety and depression is also causing increased product sales.

Additionally, during the forecast period, the market expansion is anticipated to be accelerated by cooperative efforts between pharmaceutical firms, NGOs, mental health groups, and government programs to raise public awareness. Additionally, the market is growing due to the rapidly rising research funding and the rapidly evolving healthcare industry. Also contributing significantly to the market expansion for depression screening is the rising per capita disposable income. Increased patient populations with mental illnesses and associated disorders will also ensure strong industry growth during the anticipated time frame. Additionally, numerous new advancements in antidepressants for the treatment of depression are being made in various pharmacological classes, including antipsychotics, selective norepinephrine reuptake inhibitors (SNRIs), and selective serotonin reuptake inhibitors (SSRIs).

Depression Screening Market Trends

• Growing rate of mental illness prevalence is driving the market growth

Market CAGR for depression screening is driven by the expansion of the depression screening market is the rising incidence of mental diseases worldwide. An increase in population without a corresponding improvement in human development indicators. The inability to provide for essential needs, such as education, food, shelter, water, sanitation, employment, and medical care. The likelihood of developing both physical and mental health problems is raised in such settings. Furthermore, today's hectic lifestyles and cutthroat business environments make daily life a source of stress. The incidence of mental illnesses like sadness and anxiety has increased with the modern way of life. This pattern has developed for some reasons. People are now less ashamed to talk about their mental health thanks to increased public understanding of the issue, better access to therapy, and more open communication about personal experiences.

Additionally, the official medical statistics on patients struggling with depression and other illnesses have increased as more people come out, thanks to the increased openness regarding mental health. Fewer cases may have been documented in the past since mental illness was not seen as a serious medical issue, and its victims were often stigmatized. Depression disorders issues will fuel the  market for depression treatment. Therefore, the increasing prevalence of these diseases is fueling the expansion of the international market.

For instance, the treatment of the major depressive disorder (MDD) in adults with VRAYLAR® (cariprazine) has FDA-approved as an adjuvant therapy to antidepressants. It is a medication created by AbbVie. Supported by clinical data suggesting efficacy and well-established tolerability, this supplementary medication provides a new option for patients with only a partial response to antidepressant treatments. As a result, the demand for depression screening as the projection period progresses is anticipated to increase due to rising awareness. Thus, the driving factor is depression screening market revenue.

Depression Screening Market Segment Insights

Depression Screening Disease Type Insights

The  depression screening market segmentation, based on disease type, includes major depressive disorder, anxiety distress, bipolar disorder, psychotic disorders, and others. In 2022, the major depressive disorder segment led the depression screening market in revenue due to increased nervousness and stress. Clinical depression describes major depression disorders. Regular bouts of sorrow are a sign. Disinterest in life, in general, ensues. Changes in mood, hunger, self-esteem, and sleep patterns are also present.

Depression Screening Diagnosis Insights

The  depression screening market segmentation, based on diagnosis, includes psychological tests, blood tests, pharmacogenomics testing, and others. The psychological tests segment is expected to develop at a CAGR of 5.89% over the projected period, making up the largest market share. The Mood Disorder Questionnaire, Patient Health Questionnaire, Beck Depression Inventory, Zung Self-Rating Depression Scale, Centre for Epidemiologic Studies-Depression Scale, and Hamilton Rating Scale for Depression are only psychological tests for diagnosing depression. Primary care settings often use the Mood Disorders Questionnaire and the Hypomania Checklist-32 (HCL-32) to test for bipolar disorder.

Depression Screening End-User Insights

The  depression screening market segmentation, based on end-user, includes hospitals & clinics, home-based, research institutes, and academic institutes. The segment with the largest market share in hospitals & clinics is expected to grow fastest at a CAGR of 5.89% over the next several years. Because it is common practice for medical doctors, NPs, and LCSWs (licensed clinical social workers) to use a general screening instrument containing the PHQ-9 in hospitals and clinics.

Figure 1  Depression Screening Market by End-User, 2022 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

The first medication particularly created to treat severe postpartum depression, a disorder that impacts thousands of new moms in the United States each year, has been approved by federal health officials. The Food and Medicine Administration approved the medicine Zurzuvae for individuals suffering from severe depression connected to delivery or pregnancy. For 14 days, one pill is taken each day. The new medication is made by Sage Therapeutics, which also produces an infused drug that is administered intravenously over three days in a medical setting. Although the FDA authorized the medication in 2019, its $34,000 price and logistical challenges prevent it from being used widely.

Depression Screening Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific, and the Rest of the World. The North American depression screening market will dominate because of developed healthcare infrastructure, rising technical advancements in mental health, and a well-established approval process framework. In addition, with an increased physician, improvements in treatment effectiveness, and the rise of the sedentary lifestyle because of these factors, depression screening there are expected to be significant growth in the coming years.

Further, the major countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

Figure 2  DEPRESSION SCREENING MARKET SHARE BY REGION 2022 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database, and Analyst Review

Europe’s depression screening market accounts for the second-largest market share due to an increase prevalence of mental diseases, the dynamic nature of the healthcare industry, and the ever-increasing cost of medical care. Further, the German depression screening market held the largest market share, and the UK depression screening market was the fastest-growing market in the European region.

The Asia-Pacific depression screening market is expected to grow at the fastest CAGR from 2023 to 2032 due to the increased number of individuals with mental illness and related illnesses, the ease with which cutting-edge diagnostic and therapeutic technologies are available, and the growing funding for research. Moreover, China’s depression screening market held the largest market share, and the Indian depression screening market was the fastest-growing market in the Asia-Pacific.

Depression Screening Key Market Players & Competitive Insights

Leading market players are investing heavily in research and development to expand their product lines, which will help the depression screening market grow even more. There are some strategies for action that market participants are implementing to increase their presence around the world's  footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, the depression screening industry must offer cost-effective items.

Manufacturing locally to minimize operational costs is one of the key business tactics manufacturer use in the  depression screening industry to benefit clients and increase the market sector. In recent years, the depression screening industry has offered some of the most significant technological advancements. Major players in the depression screening market, including Medtronic (Ireland), Pearson (UK), PAR, Inc. (US), SIGMA Assessment Systems Inc. (US), Siemens Healthineers (Germany), Danaher Corporation (US), National Psychological Corporation (India), Bruker (US), Multi-Health Systems Inc. (US), Nedley Health (US), and others are attempting to increase market demand by investing in research and development operations.

Pearson develops engaging and informative educational opportunities with a focus on practical application. Pearson has earned the trust of over 160 million customers throughout the world. Our products and services enable people to take daily steps toward their ideal life, whether professional development, academic advancement, higher grades, or language acquisition. The consumer always comes first in our minds. To keep up with their ever-changing educational requirements, we are expanding the number of digital items in our diversified offering. It allows us to be there for more individuals at critical junctures in their lives. In May 2023, Eric Dier, a footballer for England and Tottenham, and Pearson, a learning firm, joined forces to help the future generation avoid the same linguistic regrets as today's UK adults in light of recent studies highlighting the difficulties faced by monolingual Britons.

Professionals in the field widely use psychological evaluation items published by PAR. Our family-run business in the United States is made up of exceptional individuals who take great every customer. We appreciate the vital contributions our clients make in a variety of fields, including healthcare (both public and private), education (both K-12 and higher), law enforcement, forensics, research, and business (both domestic and international). Our clients are changing the world, one relationship at a time, no matter where they may be. We hope to be a reliable resource and partner for the greatest assessment tools to support that effort. In January 2023, the largest producer of psychological assessment tools, PAR, stated that their yearly customer donation would be given to Prevent Child Abuse America. In the United States, Prevent Child Abuse America is the oldest and largest group working Dedicated to preventing child abuse and neglect. The group's objective is to spread the word about scientifically-based initiatives and services that help children, families, and communities flourish.

Key Companies in the Depression Screening Market include

• Medtronic (Ireland)


• Pearson (UK)


• PAR, Inc. (US)


• SIGMA Assessment Systems Inc. (US)


• Siemens Healthineers (Germany)


• Danaher Corporation (US)


• National Psychological Corporation (India)


• Bruker (US)


• Multi-Health Systems Inc. (US)


• Nedley Health (US)


• Others

Depression Screening Industry Developments

May 2022 Bruker (USA) has improved its ultima 2pplus multiphoton microscope to include better 3D holographic stimulation for optogenetics.

March 2023 Pearson, the world’s largest educational organization, and Persona Education, an online service that helps students grow personally and professionally, have joined forces for a trial run. We are collaborating on digital badge programs to help GCSE students build 22 "life skills," or social and emotional competencies.

Depression Screening Market Segmentation

Depression Screening Disease Type Outlook

• Major Depressive Disorder


• Anxiety Distress


• Bipolar Disorder


• Psychotic Disorders


• Others

Depression Screening Diagnosis Outlook

• Psychological Tests


• Blood Tests


• Pharmacogenomics Testing


• Others

Depression Screening End-User Outlook

• Hospitals and Clinics


• Home-based


• Research Institutes


• Academic Institutes

Depression Screening Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America
  
  
  
  

Report Scope:

Depression Screening Report Scope

Report Attribute/Metric	Details
Market Size 2022	USD 0.67 Billion
Market Size 2023	USD 0.71  Billion
Market Size 2032	USD 1.12  Billion
Compound Annual Growth Rate (CAGR)	5.89% (2023-2032)
Base Year	2022
Market Forecast Period	2023-2032
Historical Data	2018- 2022
Market Forecast Units	Value (USD Billion)
Report Coverage	Revenue Forecast, Market Competitive Landscape, Growth Factors, and Trends
Segments Covered	Disease Type, Diagnosis, End-User, and Region
Geographies Covered	North America, Europe, Asia Pacific, Aircraft Type, and the Rest of the World
Countries Covered	The US, Canada, German, France, UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil
Key Companies Profiled	Medtronic (Ireland), Pearson (UK), PAR, Inc. (US), SIGMA Assessment Systems Inc. (US), Siemens Healthineers (Germany), Danaher Corporation (US), National Psychological Corporation (India), Bruker (US), Multi-Health Systems Inc. (US), Nedley Health (US), and Others
Key Market Opportunities	The rapid development of mental health-related digital health technology
Key Market Dynamics	The increasing rate of depression screening

Frequently Asked Questions (FAQ) :